[go: up one dir, main page]

DE602005009687D1 - Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren - Google Patents

Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren

Info

Publication number
DE602005009687D1
DE602005009687D1 DE602005009687T DE602005009687T DE602005009687D1 DE 602005009687 D1 DE602005009687 D1 DE 602005009687D1 DE 602005009687 T DE602005009687 T DE 602005009687T DE 602005009687 T DE602005009687 T DE 602005009687T DE 602005009687 D1 DE602005009687 D1 DE 602005009687D1
Authority
DE
Germany
Prior art keywords
receptor modulators
glucocorticoid receptor
condensed ring
compounds
azadecalin compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005009687T
Other languages
English (en)
Inventor
Robin D Clark
Nicholas C Ray
Paul M Blaney
Christopher A Hurley
Karen Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of DE602005009687D1 publication Critical patent/DE602005009687D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
DE602005009687T 2004-03-09 2005-03-09 Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren Expired - Lifetime DE602005009687D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55183604P 2004-03-09 2004-03-09
PCT/US2005/008049 WO2005087769A1 (en) 2004-03-09 2005-03-09 Fused ring azadecalin glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
DE602005009687D1 true DE602005009687D1 (de) 2008-10-23

Family

ID=34961932

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005009687T Expired - Lifetime DE602005009687D1 (de) 2004-03-09 2005-03-09 Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren

Country Status (17)

Country Link
US (4) US7928237B2 (de)
EP (1) EP1735308B1 (de)
JP (1) JP4931794B2 (de)
KR (1) KR101185281B1 (de)
CN (1) CN101027301B (de)
AT (1) ATE407934T1 (de)
AU (1) AU2005222421B2 (de)
CA (1) CA2558899C (de)
CY (1) CY1108621T1 (de)
DE (1) DE602005009687D1 (de)
DK (1) DK1735308T3 (de)
ES (1) ES2313317T3 (de)
IL (1) IL177982A (de)
NZ (1) NZ550362A (de)
PT (1) PT1735308E (de)
WO (1) WO2005087769A1 (de)
ZA (1) ZA200608306B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558899C (en) * 2004-03-09 2013-02-05 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
US20100261693A1 (en) * 2007-10-17 2010-10-14 Ulmann Andre Method for treating cushing's syndrome
CA2742964C (en) * 2008-11-07 2020-07-07 University Of Sheffield Medicament and method of diagnosis
EP2429529B1 (de) * 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Feststoffformen und herstellungsverfahren dafür
WO2011053574A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
JP5858929B2 (ja) * 2010-01-15 2016-02-10 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｄｅｘおよびｇｄｆ８を用いたスクリーニングアッセイ
BR112013004322A2 (pt) * 2010-08-27 2016-06-21 Corcept Therapeutics Inc moduladores de azadecalin fundidos com piridil-aminas
WO2012094618A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US9006568B2 (en) 2012-02-15 2015-04-14 Phillips 66 Company Synthesis of photovoltaic conjugated polymers
WO2013130420A1 (en) * 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
SG11201407682TA (en) * 2012-05-25 2014-12-30 Corcept Therapeutics Inc Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2014088795A1 (en) 2012-12-03 2014-06-12 Phillips 66 Company Benzo [1,2-b:4,5-b'] dithiophene-thienothiophene based conjugated polymers
EP4219494A1 (de) * 2013-11-25 2023-08-02 Corcept Therapeutics Incorporated Octahydrokondensierte azadekalin-glucocorticoid-rezeptor-modulatoren
WO2015077537A1 (en) * 2013-11-25 2015-05-28 Corcept Therapeutics, Inc. Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators
EP3265127B1 (de) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepriston und octreotid zur verwendung bei der behandlung des cushing-syndroms bei einem patienten mit einem adrenocorticotropen hormon (acth) sezernierenden pankreatischen neuroendokrinen tumor
CA2978960C (en) 2015-03-30 2023-05-02 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CA2994422A1 (en) * 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
US9911919B2 (en) 2015-10-01 2018-03-06 Phillips 66 Company Process of manufacturing an electron transport material
US10312448B2 (en) 2015-10-01 2019-06-04 Phillips 66 Company Process of manufacturing an electron transport material
WO2017058406A1 (en) 2015-10-01 2017-04-06 Phillips 66 Company Formation of films for organic photovoltaics
US10418555B2 (en) 2015-10-01 2019-09-17 Phillips 66 Company Formation of films for organic photovoltaics
US9905769B2 (en) 2015-10-01 2018-02-27 Phillips 66 Company Process of manufacturing an electron transport material
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
PH12018501848B1 (en) 2016-03-01 2024-02-23 Corcept Therapeutics Inc The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
CN110475558A (zh) 2017-03-09 2019-11-19 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用
FI3600282T3 (fi) 2017-03-31 2025-11-07 Corcept Therapeutics Inc Glukokortikoidireseptorien modulaattoreita kohdunkaulan syövän hoitoon
JP7670462B2 (ja) 2017-06-20 2025-04-30 コーセプト セラピューティクス， インコーポレイテッド 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3121193C (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2020172501A1 (en) 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US20220288091A1 (en) 2019-03-18 2022-09-15 Lynnette K. NIEMAN Method for Improving Insulin Sensitivity
US12440487B2 (en) 2019-10-16 2025-10-14 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
JP7569492B2 (ja) 2019-12-11 2024-10-18 コーセプト セラピューティクス， インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
WO2021127376A1 (en) 2019-12-21 2021-06-24 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
US20230053364A1 (en) 2020-01-29 2023-02-23 Corcept Therapeutics Incorporated Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (sgrms) and antibody checkpoint inhibitors
EP4103180A4 (de) * 2020-02-10 2024-03-13 Corcept Therapeutics Incorporated Verfahren zum stimulieren einer anti-tumor-reaktion unter verwendung eines selektiven glucocorticoid-rezeptormodulators
BR112022026201A2 (pt) 2020-06-22 2023-01-17 Corcept Therapeutics Inc Antagonistas do receptor de glicocorticoide de indazol quaternários
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2022166810A1 (zh) * 2021-02-03 2022-08-11 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
JP2025501553A (ja) 2021-12-21 2025-01-22 コーセプト セラピューティクス， インコーポレイテッド 二環式インダゾールグルココルチコイド受容体拮抗薬
CA3243549A1 (en) 2021-12-21 2023-06-29 Corcept Therapeutics Incorporated INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS
CA3258258A1 (en) * 2022-06-28 2024-01-04 Corcept Therapeutics Incorporated PROCESSES FOR PREPARING HETEROARYL-KETONE FUSED AZADECALINE GLUCOCORTICOID RECEPTOR MODULATORS
KR20250073629A (ko) 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
EP4608402A1 (de) 2022-10-28 2025-09-03 Corcept Therapeutics Incorporated Behandlung von amyotropher lateralsklerose mit dazucorilant
EP4669645A1 (de) * 2023-02-24 2025-12-31 Corcept Therapeutics Incorporated Verfahren zur herstellung von zwischenprodukten aus heteroaryl-keton-kondensierten azadekalin-glucocorticoid-rezeptormodulatoren
WO2025152964A1 (en) * 2024-01-15 2025-07-24 Insilico Medicine Ip Limited Novel compounds as glucocorticoid receptor modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
JP4498602B2 (ja) * 1998-03-10 2010-07-07 リサーチ・トライアングル・インスティチュート 新規なオピエート化合物、その調製法及び使用法
GB9911053D0 (en) * 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
JP4745609B2 (ja) * 2002-01-22 2011-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用
CA2558899C (en) * 2004-03-09 2013-02-05 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
EP2429529B1 (de) * 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Feststoffformen und herstellungsverfahren dafür

Also Published As

Publication number Publication date
EP1735308A1 (de) 2006-12-27
IL177982A (en) 2012-09-24
JP4931794B2 (ja) 2012-05-16
CY1108621T1 (el) 2014-04-09
US20110166110A1 (en) 2011-07-07
JP2007528417A (ja) 2007-10-11
WO2005087769A1 (en) 2005-09-22
HK1104813A1 (en) 2008-01-25
US20120225856A1 (en) 2012-09-06
KR20070029684A (ko) 2007-03-14
CN101027301A (zh) 2007-08-29
ES2313317T3 (es) 2009-03-01
US20070281928A1 (en) 2007-12-06
IL177982A0 (en) 2006-12-31
US8557839B2 (en) 2013-10-15
EP1735308B1 (de) 2008-09-10
US20140179671A1 (en) 2014-06-26
DK1735308T3 (da) 2009-01-19
PT1735308E (pt) 2008-12-02
ZA200608306B (en) 2009-02-25
US7928237B2 (en) 2011-04-19
CA2558899A1 (en) 2005-09-22
CA2558899C (en) 2013-02-05
CN101027301B (zh) 2011-06-29
ATE407934T1 (de) 2008-09-15
NZ550362A (en) 2010-06-25
AU2005222421A1 (en) 2005-09-22
AU2005222421B2 (en) 2010-09-23
KR101185281B1 (ko) 2012-09-21

Similar Documents

Publication Publication Date Title
DE602005009687D1 (de) Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren
CY1110491T1 (el) Διαμορφωτες του υποδοχεα γλυκοκορτικοειδους αζαδεκαλινης
ATE473744T1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
DK1521733T3 (da) Modulatorer af glucocorticoid receptoren
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
DK2060570T3 (da) Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
TW200705255A (en) Ring management
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
UY28646A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
DK1987357T3 (da) Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf
UY28645A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
MA28580B1 (fr) 3-(4-hétéroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de récepteurs de chimiokines
NO20060775L (no) Muskarine acetylkolinreseptorantagonister
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
EA200700659A1 (ru) Циклизация пептидов
MY145145A (en) Fused pyrazole-containing heterocyclic compounds as serotonin receptor modulators
UA4679U (uk) Поручень для міського транспортного засобу

Legal Events

Date Code Title Description
8364 No opposition during term of opposition